|
 |
|
|||||||
|
|||||||||
© 2006 The American Thoracic Society
doi: 10.1513/pats.200605-114LR
Controversies, Uncertainties and Future Research on the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow, Scotland; Hôpital Antoine-Béclère, Clamart, France; and University of California, San Diego, La Jolla, California
Correspondence and requests for reprints should be addressed to Andrew Peacock, M.D., Scottish Pulmonary Vascular Unit, Level 8 Western Infirmary, Dumbarton Road, Glasgow, G11 6NT Scotland. E-mail: apeacock{at}udcf.gla.ac.uk
ABSTRACT
A number of controversies exist regarding the pathophysiology, natural history, diagnosis, and treatment of chronic thromboembolic pulmonary hypertension (CTEPH). Although CTEPH is regarded by many to be a complication of pulmonary embolism (PE) arising subsequent to venous thromboembolism (VTE)—the embolic hypothesis—it has been suggested that PE is rarely the sole cause of CTEPH and that primary arteriopathy with secondary in situ thrombosis may be relevant in the pathogenesis and progression of the disease—the thrombotic hypothesis. A number of lines of evidence support this. Only about half of patients referred with suspected CTEPH have a history of VTE. In addition, data suggest that acute PE is often diagnosed, and possibly misdiagnosed, in patients with preexisting pulmonary artery pathology. There has been much research and debate on the importance of distal arteriopathy in both the initiation and progression of CTEPH. Histopathologic studies have indicated distinct overlap in the microvascular pathology of CTEPH and idiopathic pulmonary arterial hypertension (IPAH), and it has been queried whether class IV CTEPH (increased pulmonary vascular resistance due to distal arteriopathy in the absence of central organized thrombi) and IPAH represent extremes of a disease continuum. Together, these issues may impact on effective diagnosis, preoperative screening criteria for pulmonary endarterectomy surgery, and the likelihood of persistent pulmonary hypertension or even mortality after surgery. They are particularly relevant when considering the possible future use of medical therapies in long-term disease management.
Key Words: arteriopathy • endarterectomy • idiopathic pulmonary arterial hypertension • pulmonary embolism • therapy
This article has been cited by other articles:
|
|
 |
|
  O. Mercier, E. Sage, M. de Perrot, L. Tu, E. Marcos, B. Decante, B. Baudet, P. Herve, P. Dartevelle, S. Eddahibi, et al. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1538 - 1546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Lang Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options Eur. Respir. Rev., March 1, 2009; 18(111): 24 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Couturaud, I. Frachon, and C. Leroyer Chronic thromboembolic pulmonary hypertension: a tribute to pulmonary endarterectomy Eur. Respir. J., February 1, 2009; 33(2): 230 - 232. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Castaner, X. Gallardo, E. Ballesteros, M. Andreu, Y. Pallardo, J. M. Mata, and L. Riera CT Diagnosis of Chronic Pulmonary Thromboembolism RadioGraphics, January 1, 2009; 29(1): 31 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rich and M. Rabinovitch Diagnosis and Treatment of Secondary (Non-Category 1) Pulmonary Hypertension Circulation, November 18, 2008; 118(21): 2190 - 2199. [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Rubin, M. M. Hoeper, W. Klepetko, N. Galie, I. M. Lang, and G. Simonneau Current and Future Management of Chronic Thromboembolic Pulmonary Hypertension: From Diagnosis to Treatment Responses Proceedings of the ATS, September 1, 2006; 3(7): 601 - 607. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
